BE2011C004I2 - - Google Patents

Info

Publication number
BE2011C004I2
BE2011C004I2 BE2011C004C BE2011C004C BE2011C004I2 BE 2011C004 I2 BE2011C004 I2 BE 2011C004I2 BE 2011C004 C BE2011C004 C BE 2011C004C BE 2011C004 C BE2011C004 C BE 2011C004C BE 2011C004 I2 BE2011C004 I2 BE 2011C004I2
Authority
BE
Belgium
Application number
BE2011C004C
Other languages
French (fr)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BE2011C004I2 publication Critical patent/BE2011C004I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2011C004C 1999-06-22 2011-02-03 BE2011C004I2 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/338,185 US6403567B1 (en) 1999-06-22 1999-06-22 N-pyrazole A2A adenosine receptor agonists

Publications (1)

Publication Number Publication Date
BE2011C004I2 true BE2011C004I2 (it) 2019-05-21

Family

ID=23323763

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C004C BE2011C004I2 (it) 1999-06-22 2011-02-03

Country Status (27)

Country Link
US (9) US6403567B1 (it)
EP (1) EP1189916B1 (it)
JP (1) JP4727880B2 (it)
KR (1) KR100463300B1 (it)
CN (1) CN1167709C (it)
AR (1) AR024441A1 (it)
AT (1) ATE256141T1 (it)
AU (1) AU760806B2 (it)
BE (1) BE2011C004I2 (it)
BR (1) BRPI0011856B8 (it)
CA (1) CA2377746C (it)
CY (1) CY2011002I2 (it)
DE (2) DE122011000010I1 (it)
DK (1) DK1189916T3 (it)
ES (1) ES2209974T3 (it)
FR (1) FR11C0004I2 (it)
HK (1) HK1044952B (it)
IL (2) IL147198A0 (it)
LU (1) LU91785I2 (it)
MX (1) MXPA01013325A (it)
NO (2) NO322457B1 (it)
NZ (1) NZ516334A (it)
PT (1) PT1189916E (it)
TR (1) TR200200588T2 (it)
TW (1) TWI230161B (it)
WO (1) WO2000078779A2 (it)
ZA (1) ZA200200301B (it)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) * 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US20020012946A1 (en) * 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US20050059068A1 (en) * 2001-05-23 2005-03-17 Stratagene California Compositions and methods using dendrimer-treated microassays
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
HUP0402591A2 (hu) 2002-02-15 2005-09-28 Cv Therapeutics, Inc. Polimer bevonat orvosi eszközök számára
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) * 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US6914053B2 (en) 2002-09-09 2005-07-05 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
PT2366396E (pt) * 2004-01-27 2013-10-03 Gilead Sciences Inc Imagiologia de perfusão miocárdica utilizando agonistas do receptor de adenosina
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
DK1758596T3 (da) * 2004-05-26 2010-07-26 Inotek Pharmaceuticals Corp Purinderivater som adenosin-A1-receptoragonister og fremgangsmåder til anvendelse deraf
US7863253B2 (en) * 2004-09-20 2011-01-04 Inotek Pharmaceuticals Corporation Purine Derivatives and methods of use thereof
JP2008517063A (ja) * 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
CA2627319A1 (en) * 2005-11-30 2007-06-07 Prakash Jagtap Purine derivatives and methods of use thereof
PL1989214T3 (pl) * 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
US20070183995A1 (en) * 2006-02-09 2007-08-09 Conopco, Inc., D/B/A Unilever Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
DE102006020349A1 (de) 2006-04-28 2007-10-31 Mahle International Gmbh Kolbenmotor und zugehöriges Betriebsverfahren
US7691825B2 (en) * 2006-06-06 2010-04-06 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor agonists
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
BRPI0716174A2 (pt) * 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
BRPI0718792A2 (pt) * 2006-11-10 2013-12-03 Novartis Ag Compostos orgânicos
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
JP2008285478A (ja) * 2007-04-16 2008-11-27 Santen Pharmaceut Co Ltd アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
RU2443708C2 (ru) * 2007-05-17 2012-02-27 Си Ви Терапьютикс, Инк. Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций
JP5349461B2 (ja) * 2007-05-17 2013-11-20 ギリアード・パロ・アルト・インコーポレイテッド Ａ２ａ−アデノシン受容体アゴニストおよびその多形体を調製するための方法
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US20090207759A1 (en) * 2008-02-15 2009-08-20 Andreasen Flemming S System and method for providing a converged wireline and wireless network environment
WO2009149392A1 (en) 2008-06-06 2009-12-10 Hollis-Eden Pharmaceuticals, Inc. Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
CN102164591A (zh) * 2008-09-29 2011-08-24 吉利德科学股份有限公司 速率控制剂和A-2-α受体拮抗剂的组合用于多检测器计算机化断层显像方法
US7957314B2 (en) * 2008-12-12 2011-06-07 Cisco Technology, Inc. System and method for provisioning charging and policy control in a network environment
SG10201502588UA (en) 2010-01-11 2015-05-28 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
MX2012010724A (es) 2010-03-26 2012-11-12 Inotek Pharmaceuticals Corp Metodo para reducir la presion intraocular en seres humanos empleando n6-ciclopentiladenosina (cpa), derivados de cpa o profarmacos de los mismos.
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US9215588B2 (en) 2010-04-30 2015-12-15 Cisco Technology, Inc. System and method for providing selective bearer security in a network environment
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
US8859522B2 (en) 2011-04-27 2014-10-14 Reliable Biopharmaceutical Corporation Processes for the preparation of regadenoson and a new crystalline form thereof
CZ308577B6 (cs) * 2011-08-18 2020-12-16 Farmak, A. S. Způsob přípravy 2-(4-methoxykarbonylpyrazol-1-yl)adenosinu a 2-(4-ethoxykarbonylpyrazol-1-yl)adenosinu
CZ304053B6 (cs) 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
US20150290236A1 (en) * 2012-11-30 2015-10-15 Leiutis Pharmaceuticals Pvt. Ltd. Pharmaceutical compositions of regadenoson
CN105188714A (zh) 2013-03-15 2015-12-23 伊诺泰克制药公司 眼用配制品
EP3760637A3 (en) 2013-04-11 2021-04-07 AMRI Italy S.r.l. Stable solid forms of regadenoson
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
US9624258B2 (en) 2013-05-30 2017-04-18 Biophore India Pharmaceuticals Pvt. Ltd. Polymorph of regadenoson
CN104513241B (zh) * 2013-09-30 2017-02-08 浙江海正药业股份有限公司 瑞加德松新中间体及其制备方法和应用
CN104744540A (zh) * 2013-12-26 2015-07-01 上海紫源制药有限公司 一种制备瑞加德松的方法
CN105085593A (zh) * 2014-04-21 2015-11-25 上海紫源制药有限公司 瑞加德松的晶型及其制备方法
US10442832B2 (en) 2015-02-06 2019-10-15 Apicore Us Llc Process of making regadenoson and novel polymorph thereof
US9809617B2 (en) 2015-07-03 2017-11-07 Shanghai Ziyuan Pharmaceutical Co., Ltd. Crystal form of regadenoson and preparation method thereof
CN106397442B (zh) * 2015-07-28 2020-03-27 国药集团国瑞药业有限公司 一种瑞加德松的纯化方法
JP7100854B2 (ja) 2017-01-13 2022-07-14 東菱薬品工業株式会社 好中球活性化調節剤
WO2019191389A1 (en) 2018-03-29 2019-10-03 Johnson Matthey Public Limited Company Solid-state forms of regadenoson, their use and preparation
US10815265B2 (en) 2018-06-29 2020-10-27 Usv Private Limited Process for preparation of regadenoson and polymorphs thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
BE787064A (fr) 1971-08-03 1973-02-01 Philips Nv Dispositif magnetique comportant des domaines
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4990498A (en) * 1988-04-26 1991-02-05 Temple University-Of The Commonwealth System Of Higher Education 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (de) * 1988-09-15 1990-03-22 Bayer Ag Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5270304A (en) 1988-11-15 1993-12-14 Yamasa Shoyu Kabushiki Kaisha Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
ES2077070T3 (es) 1989-06-20 1995-11-16 Yamasa Shoyu Kk Intermedio de sintesis de 2-alquiniladenosina, produccion de dicho intermedio, produccion de 2-alquiniladenosina a partir de dicho intermedio, y derivado de 2-alquiniladenosina estable.
US5032252A (en) * 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (fr) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu.
JP2740362B2 (ja) 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
JP3053908B2 (ja) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
WO1993025677A1 (en) 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
EP0601322A3 (en) 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosine deaminase inhibitor.
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
US5477857A (en) 1993-09-10 1995-12-26 Discovery Therapeutics, Inc. Diagnostic uses of hydrazinoadenosines
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
WO1995023148A1 (fr) * 1994-02-23 1995-08-31 Kyowa Hakko Kogyo Co., Ltd. Derive de la xanthine
US5704491A (en) * 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) * 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
AU7449598A (en) 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
EP1014995A4 (en) 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
US6026317A (en) 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
EP1011608A4 (en) 1998-06-08 2002-05-15 Epigenesis Pharmaceuticals Inc COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF HEART AND NEUTRAL FAILURE OR DAMAGE RELATED TO ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR CALLED BY THE ADDITION OF SPECIFIC MEDICINES
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
NZ517546A (en) 1999-08-31 2003-10-31 Univ Vanderbilt Selective antagonists of A2B adenosine receptors
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US20020012946A1 (en) * 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
CN1268610C (zh) * 2001-05-14 2006-08-09 诺瓦提斯公司 磺酰胺衍生物
IL161867A0 (en) * 2001-11-09 2005-11-20 Cv Therapeutics Inc A2b adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CA2471059C (en) * 2001-12-20 2011-04-26 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
WO2003086451A1 (en) * 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
EP1494685B1 (en) 2002-04-18 2008-12-31 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker
US7683037B2 (en) 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
PT2366396E (pt) 2004-01-27 2013-10-03 Gilead Sciences Inc Imagiologia de perfusão miocárdica utilizando agonistas do receptor de adenosina
JP2008516969A (ja) * 2004-10-15 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニストを使用した、気道のリモデリングおよび肺の炎症の予防および処置の方法
JP2008517063A (ja) * 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
JP2008527003A (ja) 2005-01-12 2008-07-24 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド 喘息又は気管支痙攣の既往歴を有する患者における心筋機能不全を検出する方法
PL1989214T3 (pl) * 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
BRPI0716174A2 (pt) * 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
JP5349461B2 (ja) 2007-05-17 2013-11-20 ギリアード・パロ・アルト・インコーポレイテッド Ａ２ａ−アデノシン受容体アゴニストおよびその多形体を調製するための方法
WO2009076580A2 (en) 2007-12-12 2009-06-18 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
CN102164591A (zh) * 2008-09-29 2011-08-24 吉利德科学股份有限公司 速率控制剂和A-2-α受体拮抗剂的组合用于多检测器计算机化断层显像方法

Also Published As

Publication number Publication date
LU91785I2 (fr) 2011-03-31
ZA200200301B (en) 2003-11-26
US20110144320A1 (en) 2011-06-16
WO2000078779A3 (en) 2001-03-15
NO322457B1 (no) 2006-10-09
NZ516334A (en) 2004-05-28
US20130058866A1 (en) 2013-03-07
US7183264B2 (en) 2007-02-27
FR11C0004I2 (fr) 2012-03-16
NO20016350L (no) 2002-02-18
CA2377746C (en) 2007-04-10
JP2003506461A (ja) 2003-02-18
US9045519B2 (en) 2015-06-02
US6642210B1 (en) 2003-11-04
US7655637B2 (en) 2010-02-02
FR11C0004I1 (fr) 2011-03-11
EP1189916A2 (en) 2002-03-27
CY2011002I1 (el) 2012-01-25
NO2011002I2 (no) 2012-10-22
CA2377746A1 (en) 2000-12-28
CY2011002I2 (el) 2012-01-25
DK1189916T3 (da) 2004-03-22
US20060052332A1 (en) 2006-03-09
MXPA01013325A (es) 2002-07-02
BR0011856B1 (pt) 2014-06-17
US7144872B2 (en) 2006-12-05
HK1044952A1 (en) 2002-11-08
US6403567B1 (en) 2002-06-11
AU760806B2 (en) 2003-05-22
DE60007127D1 (de) 2004-01-22
BR0011856A (pt) 2004-02-10
EP1189916B1 (en) 2003-12-10
TR200200588T2 (tr) 2002-09-23
ATE256141T1 (de) 2003-12-15
JP4727880B2 (ja) 2011-07-20
KR100463300B1 (ko) 2004-12-23
US20070203090A1 (en) 2007-08-30
PT1189916E (pt) 2004-03-31
US20040038928A1 (en) 2004-02-26
AR024441A1 (es) 2002-10-02
HK1044952B (zh) 2005-02-25
WO2000078779A2 (en) 2000-12-28
TWI230161B (en) 2005-04-01
KR20020028910A (ko) 2002-04-17
IL147198A0 (en) 2002-08-14
NO20016350D0 (no) 2001-12-21
CN1358191A (zh) 2002-07-10
ES2209974T3 (es) 2004-07-01
NO2011002I1 (no) 2011-03-07
US20140073596A1 (en) 2014-03-13
CN1167709C (zh) 2004-09-22
DE60007127T2 (de) 2004-09-16
US20100160620A1 (en) 2010-06-24
IL147198A (en) 2006-04-10
US8569260B2 (en) 2013-10-29
US8278435B2 (en) 2012-10-02
AU7132400A (en) 2001-01-09
BRPI0011856B8 (pt) 2021-05-25
DE122011000010I1 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
BE2018C020I2 (it)
BE2016C007I2 (it)
BE2015C057I2 (it)
BE2015C018I2 (it)
BE2014C017I2 (it)
BE2013C051I2 (it)
BE2013C020I2 (it)
BE2013C015I2 (it)
BE2013C001I2 (it)
BE2012C036I2 (it)
BE2011C004I2 (it)
BE2010C011I2 (it)
BE2008C046I2 (it)
BE1025464I2 (it)
JP2002529034A5 (it)
BE2008C047I2 (it)
BRPI0001672A2 (it)
JP2002504459A5 (it)
JP2002531814A5 (it)
BRPI0001542A2 (it)
JP2002507014A5 (it)
JP2002526762A5 (it)
JP2002524695A5 (it)
JP2002523923A5 (it)
JP2002517336A5 (it)